Covaccine is effective against beta and delta variants
For information, let us tell you that the dangerous delta variant (B.1.617.2) of Kovid-19 was found for the first time in India while the beta variant (B.1.351) was first discovered in South Africa. Research has shown that Covaccine is effective against both these variants.
In research to evaluate the neutralization potential of Covaxin, researchers found a three-fold reduction in neutralization titers, or concentration of neutralizing antibodies, against beta and delta variants. It is clear from this that covaccine produces antibodies against beta and delta variants.
Which is more deadly between beta and delta
The World Health Organization (WHO) has named the variants B.1.617.1 and B.1.617.2 of the corona virus discovered in India as Kappa and Delta. The research also revealed that this delta variant is more than 50 percent more dangerous than the alpha variant first detected in the UK, which infects people much faster.
However, scientists also say that no evidence has yet been found of the role of delta variants in deaths or high incidence of cases. The WHO has issued a statement that considers the delta variant to be more lethal than the alpha. Let us inform that in October last year, the strain (B.1.617.1) found in India was named ‘Kappa’.
Covishield was shown to be more effective in previous research
Recently, a study revealed that Covishield makes more antibodies than Covaccine. According to the news – this was revealed in the initial research of Corona Vaccine Induced Antibody Titre (COVAT). The research conducted in the meantime included those health workers who had taken doses of Covaccine or Covishield.
Previously found higher Covishield seropositivity rate
In the first days of research, the seropositivity rate to anti-spike antibodies were found to be higher in people who got Kovashield than those who took the first dose of Covaccine. It was said in this study that both the corona vaccines are effective but Kovishield has a high seropositivity rate and produces more anti-spike antibodies.
For information, let us tell you that 552 health workers were included in this research, in which 325 were men and 227 were women. 456 were given Covishield and 96 were given the first dose of Covaccine and after that the results came.
ICMR and Bharat Biotech did research together
The research on the vaccine has been done jointly by the National Institute of Virology, Indian Council of Medical Research and Bharat Biotech, Pune. The copy of this study has been uploaded by researchers from NIV, ICMR and Bharat Biotech on a website called biorxiv.
Let us also tell you that Bharat Biotech, Indian Council of Medical Research (ICMR) and National Institute of Virology (NIV) are jointly manufacturing Covaccine.
Covaccine dose prepared for children
On the other hand, doses of Covaccine have been prepared for children as well and preparations for the trial are going on. The Drug Controller General of India (DCGI) has approved the Phase 2/3 trial of Agegroup Vaccine for 2 to 18 years on May 12 itself. According to reports, volunteers from 2 years to 18 years are participating in the trial of Covaccine. Trial of covaccine on children is going on in Patna AIIMS.